What makes an antibiotic the right antibiotic ?

Paul M. Tulkens, MD, PhD

Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium <u>http://www.facm.ucl.ac.be</u>

Bayer China Anti-infective Summit 2018 Shanghai, China, 12 May 2018





With approval of the Belgian Common Ethical Health Platform – visa no. 18/V1/7042/099172



Disclosures

Industry support for work on investigational compounds from

- Cempra Pharmaceuticals ¹
- GSK
- Melinta Therapeutics ²
- The Medicine Company ³
- MerLion Pharmaceuticals
- Trius Therapeutics ⁴
- Debiopharm

Non-profit support from

- the Fond de la Recherche Scientifique (F.R.S.-FNRS)
- the *Région Wallone*
- the European Union (FP7 programme)

Influenced by my participation to the

- Belgian Drug Reimbursement Committee (CRM/CTG; up to 2006)
- EUCAST steering committee (2008-2010) and General Assembly (current)
- the Governance Body of <u>DRIVE-AB</u> (2014-2017) (an EU programme aiming at (re)designing the economic framework of the discovery, development and commercialization processes for new antibiotics)

⁴ acquired by Cubist (2014), which was then acquired by Merck (2016)




¹ merged in 2017 with and renamed as Melinta Therapeutics

² formerly RibX Pharmaceuticals; world rights holder for delafloxacin (with license to Menarini for EU and other countries)

³ antibiotic portfolio acquired by Melinta Therapeutics in 2018

The right antibiotic ? I always wondered...



https://expertconsult.inkling.com/read/mandell-douglasbennetts-infectious-diseases-8/mandell-douglas-andbennetts/cover Chapter 17: Principles of Anti-infective Therapy George M. Eliopoulos Robert C. Moellering Jr.*

"In choosing the appropriate antimicrobial agent for therapy for a given infection, a number of factors must be considered.

- First, the identity of the infecting organism must be known or, at the very least, it must be possible to arrive at a statistically reasonable guess as to its identity on the basis of clinical information.
- Second, information about the susceptibility of the infecting organism, or likely susceptibility, must be as accurate as possible.
- Finally, a series of factors specific to the patient who is being treated (and his/her disease) must be considered to arrive at the optimal choice of antimicrobial agent. "






Here are the questions ...

When choosing an antibiotic, do we know

- 1. for the organism
 - its identity and whether it is causal or not
 - its susceptibility to and the main key properties of the proposed antibiotic
- 2. for the patient
 - the antibiotic effectiveness in the specific disease
 - how to dose the antibiotic appropriately
 - how to prevent / avoid patient- and drug-related side effects
- 3. for Society
 - how to prevent emergence of resistance
 - how to get "value for money"

Please, think about what YOU would answer !







When choosing an antibiotic, do we know

- 1. for the organism
 - its identity and whether it is causal or not ?

If sample(s) is (are) available, use of all "possible" techniques

- Gram stain and direct microscopy examination...
- rapid immunological and molecular techniques...
- culture and identification (galleries / MALDI-TOF)...
- quantitative cultures

If no sample is available... we must use "bacteriological statistics"

caution:


garbage in – garbage out

> caution: possible

surprizes

- likelihood to cause a specific infection
- endogenous and/or environmental presence










Implementation of EUCAST breakpoints, January 2018



12 May 2018

Université catholique de Louvain


Bayer China Summit 2018 - Shanghai

When choosing an antibiotic, do we know


- 1. for the organism
 - its susceptibility to the proposed antibiotic

Epidemiological studies are critical for global antibiotic policy...

Figure 3.25. *Staphylococcus aureus*. Percentage (%) of invasive isolates with resistance to meticillin (MRSA), by country, EU/EEA countries, 2016




http://ecdc.europa.eu/sites/portal/files/documents/AMR-surveillance-Europe-2016.pdf



National Surveillance of Methicillin-Resistant *Staphylococcus aureus* in China Highlights a Still-Evolving Epidemiology with 15 Novel Emerging Multilocus Sequence Types

Meng Xiao,^a He Wang,^a Ying Zhao,^a Lei-Li Mao,^a Mitchell Brown,^b Yun-Song Yu,^d Matthew V. N. O'Sullivan,^{b,c} Fanrong Kong,^b Ying-Chun Xu^a


Department of Clinical Laboratory, Peking Union Medical College Hospital, and Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China^{*}, Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead Hospital, Westmead, New South Wales, Australia^b; Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia^c; Sir RunRun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China^d





When choosing an antibiotic, do we know

- 1. for the organism
 - the main key properties of the proposed antibiotic against the identified (or likely) target(s)






When choosing an antibiotic, do we know

- 1. for the organism
 - the main key properties of the proposed antibiotic against the identified (or likely) target(s)

Spectrum and mode / extent of action

• the molecular parameters that differentiate drugs ...






Bayer China Summit 2018 - Shanghai



From linezolid to tedizolid: what the structure tells us






11

When choosing an antibiotic, do we know

- 1. for the organism
 - the main key properties of the proposed antibiotic against the identified (or likely) target(s)

Spectrum and mode / extent of action

• activity against persisters, small colony variants, intracellulars, biofilms



. . .

Figure 3: Longer term time kill experiments. Change in viable cell density, means and standard errors (bars), for three independent cutures of survari each expendito different concentrations (3 × MIC, 10 × MIC and 20 × MIC) of four entibliotics. (J) CipotIbascin, (J) Gentamicia, (K) Davollin and (D) Vanomycin. doi:10.1371/journal.gopr.1001123/p001

Johnson & Levin. PLoS Genet. 13;9:e1003123. - PMID: 23300474







Figure 1 | Small colony variants. Columbia blood-agar plates that show the normal (a) and the small colony variant (b) phenotype of *Staphylococcus aureus* are shown.

Proctor et al. Nat Rev Microbiol 2006;4:295-305 - PMID: 16541137

S. aureus in human osteoblasts







Lewis et al, Nat Rev Microbiol. 2007; 5:48-56



Bayer China Summit 2018 - Shanghai




Possible answers ...

When choosing an antibiotic, do we know

- 1. for the organism
 - the main key properties of the proposed antibiotic against the identified (or likely) target(s)

Spectrum and mode / extent of action

activity against persisters, small colony variants, intrace



. . .

Figure 3. Longer term time kill experiments. Change in viable cell density, means and standard errors (ban). for three independent cubues of 5 source each expension of adfinement concentrations (5 × MIC, 10 × MIC and 20 × MIC) of four antibiotics. (U/ Epothawaris, (I) Centamicin, (IC Dwallie and (ID: Vancompcin. doi:10.1171/journal.gom.100112.god)

Johnson & Levin. PLoS Genet. 13;9:e1003123. - PMID: 23300474






Figure 1 | Small colony variants. Columbia blood-agar plates that show the normal (a) and the small colony variant (b) phenotype of *Staphylococcus aureus* are shown.

Proctor et al. Nat Rev Microbiol 2006;4:295-305 - PMID: 16541137

S. aureus in human osteoblasts



Kalinka et al., Int J Med Microbiol. 2014; 304:1038-49 - PMID: 25129555



a new

frontier ?

Lewis et al, Nat Rev Microbiol. 2007; 5:48-56



Bayer China Summit 2018 - Shanghai



Possible answers for the patient ...

When choosing an antibiotic, do we know

- 2. for the patient
 - the antibiotic effectiveness in the specific disease ?

Are potent in vitro antibiotics always potent in vivo? ...

The daptomycin story...

Inhibition of Daptomycin by Pulmonary Surfactant In Vitro Modeling and Clinical Impact

Jared A. Silverman, Lawrence I. Mortin, Andrew D. G. VanPraagh, Tongchuan Li, and Jeff Alder Cubist Pharmaceuticals, Lexington, Massachusetts clinical demonstration is essential !

The lipopeptide daptomycin has been approved for use in skin and skin-structure infections but has failed to meet statistical noninferiority criteria in a clinical trial for severe community-acquired pneumonia. Daptomycin exhibited an unusual pattern of activity in pulmonary animal models: efficacy in *Staphylococcus aureus* hematogenous pneumonia and inhalation anthrax but no activity against *Streptococcus pneumoniae* in simple bronchial-alveolar pneumonia. Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in inhibition of antibacterial activity. This effect was specific to daptomycin and consistent with its known mechanism of action. This represents the first example of organ-specific inhibition of an antibiotic.

caution with offlabel use ...




Silverman et al. J Infect Dis2005;191:2149-52 - PMID: 15898002



12 May 2018

Antibiotic poor penetration can explain many difficulties...



- Lamer C. et al. Antimicrob Agents Chemother 1993;37:281–286.
 Graziani AL, et al. Antimicrob Agents Chemother 1988;32:1320–1322.
- Cruciani M, et al. J Antimicrob Chemother 1996;38:865–869.
 Daschner FD et al. J Antimicrob Chemother 1987;19:359–362.




12 May 2018

Université catholique de Louvain

Possible answers for the patient ...

When choosing an antibiotic, do we know

- 2. for the patient
 - how to dose the antibiotic appropriately ?








A simple in vitro comparison

- quinolone ... **β-lactam** ... Ticarcillin Ciprofloxacin Control 01/4 MIC I'MIC $\triangle 4 MIC$ 16 MIC D64MIC 2 0 2 4 6 8 0 4 6 Time (hours) Fast and concentration-Slow and timedependent dependent
- bacteria in broth
- increasing concentrations (multiples of MIC)
- measure of the change in CFUs over time


Vogelman & Craig (1986) Jounal of Pediatrics 108:835-840







PK parameters governing the activity of antibiotics






18


How to determine which PK parameter is critical?

If you fractionate the daily dose, you change C_{max} without changing AUC_{24h}



How to determine which PK parameter is critical ?

 If you increase the dose without change of schedule, you increase BOTH C_{max} and AUC_{24h}



Université catholique de Louvain

The 3 main patterns of antibiotic PK/PD properties

(W.A. Craig, 2000; revised in 2003)

antibiotic	PK/PD parameter	What to do ?
β-lactams	time > MIC	stay > MIC as needed
macrolides, oxazolidinones, vancomycin	AUC _{24h} / MIC	give a sufficient total daily dose
quinolones aminoglycosides	peak / MIC and AUC _{24h} / MIC	obtain a peak and aim for a sufficient total daily dose


* 2d ISAP Educational Workshop, Stockholm, Sweden, 2000; revised accord. to Craig, Infect. Dis. Clin. N. Amer., 17:479-502, 2003



12 May 2018



What should you strive for ?



concentration








How to be optimal ?

If you select a β -lactam ...






UCL Université de Louvain 12 May 2018

Breakpoint setting...

Fig. 2.6 Change in log₁₀ CFUs/thigh over 24 h for various Enterobacteriaceae following treatment with multiple fluoroquinolones in neutropenic mice. Redrawn from data in Andes and Craig (2002)









Breakpoint setting: the EUCAST way




Fig. 3.4 Summary of the process of setting PK/PD breakpoints by EUCAST (Mouton et al. 2012)





Toxicodynamics: what drives linezolid toxicity...




Fig. 16.13 Linezolid C_{min} and logistic regression model for thrombocytopenia (Pea et al. 2012), reproduced with permission. The symbols refer to the C_{min} observed over time in each patient with (*top*) or without (*bottom*) thrombocytopenia. The *continuous line* represents the result of the logistic regression model. The *vertical broken line* identifies the C_{min} value predicting 50 % probability of thrombocytopenia

Theuretzbacher U, PK/PD of Oxazolidinones In: Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics, AA. Vinvk, H. Derendorf & JW Mouton eds, Springer, 2014, p 401-443





Bayer China Summit 2018 - Shanghai

Answers for the patient ...

When choosing an antibiotic, do we know

- 2. for the specific patient
 - how to prevent / avoid patient- and drug-related side effects

Aminoglycosides are concentration-dependent and need to be given once-daily both for increased efficacy and possible reduction of toxicity




Fig. 9.1 Concentration-time profile comparison of conventional q8h intermittent dosing versus the once-daily daily administration technique






Answers for the patient ...

When choosing an antibiotic, do we know

- 2. for the specific patient
 - how to prevent / avoid patient- and drug-related side effects



28



Answers for the patient ...

When choosing an antibiotic, do we know


20

- 2. for the specific patient
 - how to prevent / avoid patient- and drug-related side effects

Choosing the appropriate drug derivative can be rewarding...

Tedizolid (TZD) *vs*. linezolid (LZD) safety: Platelet counts Pooled Phase 3 Studies

DeAnda *et al.* Integrated results from 2 phase 3 studies comparing tedizolid phosphate 6 days vs. linezolid 10 days in patients with ABSSSI. Poster presented at: 53rd Interscience Congress on Antimicrobial Agents and Chemotherapy (ICAAC); September 10-13, 2013; Denver, CO. (L-203).





Here are the questions ...

When choosing an antibiotic, do we know

- 3. for the society
 - how to prevent emergence of resistance ?



Answers for Society ...

When choosing an antibiotic, do we know

- 3. for the society
 - how to prevent emergence of resistance ?

This is probably a **most difficult challenge** because

- resistance genes are already present in nature (resistome)
- bacteria quickly adapt to new environments (mutation/selection)




Fig. 1 The antibiotic resistome gene flow in environments, human, and animals. We propose that the antibiotic resistome gene flow is "form the natural environments" and "to the natural environments." The natural environments are the reservoirs for antibiotic resistome. The original ARGs in environmental bacteria can be captured by human or animal pathogens and gradually evolved under the antibiotic selection pressure and become qualified. These ARGs or ARG-bearing bacteria are then disseminated back to the natural environments due to the human activities on producing and using antibiotics. In most cases, the ARGs are more easily transferred within respective ecological niches (the natural environments, and the human- and animal-associated environments). This resistance gene flow scenario is not very applicable to antibiotic resistance caused by chromosomal mutation.



Hu et al. Front Med 2017;11:161-168 - PMID: 28500429



Answers for the Society ...

When choosing an antibiotic, do we know

- 3. for the society
 - how to prevent emergence of resistance ?

This is probably a most difficult challenge because
resistance genes are already present in nature (re
bacteria quickly adapt to new environments (muta)

If everyone were cast in the same mould, there would be no such thing as beauty — Darwin






Fig. 1 The antibiotic resistome gene flow in environments, human, and animals. We propose that the antibiotic resistome gene flow is "form the natural environments" and "to the natural environments." The natural environments are the reservoirs for antibiotic resistome. The original ARGs in environmental bacteria can be captured by human or animal pathogens and gradually evolved under the antibiotic selection pressure and become qualified. These ARGs or ARG-bearing bacteria are then disseminated back to the natural environments due to the human activities on producing and using antibiotics. In most cases, the ARGs are more easily transferred within respective ecological niches (the natural environments, and the human- and animal-associated environments). This resistance gene flow scenario is not very applicable to antibiotic resistance caused by chromosomal mutation.



Hu et al. Front Med 2017;11:161-168 - PMID: 28500429

Université

MIC may increase during treatment !



Change in MIC of antibiotics used in empiric antipseudomonal therapy (nosocomial pneumonia; intensive care units) towards the isolate identified before onset of therapy (D0) *vs.* the last isolate (DL) collected from the same patient and with clonal similarity with the first isolate. Differences were analyzed using both raw and log₂ transformed data and found significant by both non-parametric (Wilcoxon matched pair test) and parametric (two-tailed paired t-test) analysis.



Bayer China Summit 2018 - Shanghai

Riou et al. Int J Antimicrob Agents. 2010 Dec;36(6):513-22.



Optimization may prevent emergence of resistance

J Antimicrob Chemother 2017; **72**: 1421–1428 doi:10.1093/jac/dkx001 Advance Access publication 31 January 2017 Journal of Antimicrobial Chemotherapy


Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria

Vincent H. Tam¹*, Kai-Tai Chang¹, Jian Zhou¹, Kimberly R. Ledesma¹, Kady Phe¹, Song Gao¹, Françoise Van Bambeke², Ana María Sánchez-Díaz³, Laura Zamorano⁴, Antonio Oliver⁴ and Rafael Cantón³

¹University of Houston, Houston, TX, USA; ²Pharmacologie Cellulaire et Moléculaire & Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium; ³Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; ⁴University Hospital Son Espases, Instituto de Investigación Sanitaria de Palma, Palma de Mallorca, Spain

Tam et al. J Antimicrob Chemother 2017;72:1421-1428 - PMID: 28158470

Simulation of serum concentration levels (hollow fibers model)





Optimization may prevent emergence of resistance




Figure 2. Typical bacterial profiles for WT *P. aeruginosa*. Placebo control (a). Ceftazidime at 500 mg every 8 h ($C_{min}/MIC = 2.9$) (b). Ceftazidime at 3000 mg every 8 h ($C_{min}/MIC = 7.7$) (c). Data are shown as mean \pm SD.




Figure 3. Drug exposures (C_{min} /MIC) stratified by outcomes. Each data point represents a hollow-fibre infection model experiment. The most significant threshold (C_{min} /MIC \geq 3.8) is depicted by the horizontal broken line.


To prevent emergence of resistance, C_{min} of β-lactams must stay > 4 x MIC (mean), which commands higher dosages...

Tam et al. J Antimicrob Chemother 2017;72:1421-1428 - PMID: 28158470



Université catholique de Louvain

Appropriately dosed antibiotics may avoid resistance creep



* Moxifloxacin was introduced in Belgium in 2001 and became the almost only fluoroquinolone used for RTI since 2004

From data of a national collection

- Non invasive respiratory tract infections
- similar results in 2008 for a collection of *S. pneumoniae* from clinically-confirmed CAP (n=132)
- Surveys from the Belgian Scientific Institute for Public Health for *S. pneumoniae* from community isolates (n=156 in 1999 and 312 in 2014)
- Data available yearly for 1999 through 2014 at <u>http://www.iph.fgov.be</u>

Vanhoof *et al.* 19th ECCMID, Helsinki, 2009 Ceyssens *et al.* 35th RICAI, Paris, 2015 Ceyssens *et al.* PLoS One 2016;11:e0154816 (17 pages) - PMID 27227336

36



12 May 2018



Why no resistance of *S. pneumoniae* to moxifloxacin ?


ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2007, p. 1315–1320 0066-4804/07/\$08.00+0 doi:10.1128/AAC.00646-06 Copyright © 2007, American Society for Microbiology. All Rights Reserved. Vol. 51, No. 4

Fluoroquinolone Resistance in *Streptococcus pneumoniae*: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin⁷

Kerry L. LaPlante,^{1,2,4}⁺ Michael J. Rybak,^{1,2,3,4}* Brian Tsuji,^{1,2,4}[±] Thomas P. Lodise,⁶ and Glenn W. Kaatz^{1,3,5}

Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy,¹ Department of Pharmacy Practice,² and School of Medicine,³ Wayne State University, Detroit Receiving Hospital and University Health Center,⁴ and John D. Dingell Veterans Affairs Medical Center,⁵ Detroit, Michigan, and Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York⁶

LaPlante et al. Antimicrob Agents Chemother 2007;51:1315-20 - PMID: 17296740



Clinical doses of moxifloxacin exceeded the fAUC/MIC resistance breakpoint against wild-type *S. pneumoniae*, whereas those of levofloxacin (500 and 750 mg) were associated with first- and second-step mutations.


Additionally, moxifloxacin breakpoints were significantly lower (P < 0.002) than those of gatifloxacin.

The order of resistance development determined from fAUC/MIC breakpoints was levofloxacin > moxifloxacin = gemifloxacin, which may be related to structural differences within the class.







What differentiates fluoroquinolones ?



Pharmacokinetics and "resistance" breakpoint vs. MIC



The risk for resistance to fluoroquinolones ... the MPC !



Time after administration

concept from Drlica & Zhao, Rev. Med. Microbiol. 2004, 15:73-80




30 Nov 2017

Not All Fluoroquinolones Are Equal



MPC: moxifloxacin vs levofloxacin









What about the recommendations for CAP ?

ORIGINAL ARTICLE

10.1111/j.1469-0691.2011.03672.x

Guidelines for the management of adult lower respiratory tract infections - Full version

M. Woodhead¹, F. Blasi², S. Ewig³, J. Garau⁴, G. Huchon⁵, M. leven⁶, A. Ortqvist⁷, T. Schaberg⁸, A. Torres⁹, G. van der Heijden¹⁰, R. Read¹¹ and T. J. M. Verheij¹² Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases

Recommendation:

Aminopenicillin \pm macrolide^{a,b} Aminopenicillin/ β -lactamase inhibitor^a \pm macrolide^b Non-antipseudomonal cephalosporin Cefotaxime or ceftriaxone \pm macrolide^b Levofloxacin^a <u>Moxifloxacin^{a,c}</u> Penicillin G \pm macrolide

^aCan be applied as sequential treatment using the same drug. ^bNew macrolides preferred to erythromycin.

^cWithin the fluoroquinolones, moxifloxacin has the highest

antipneumococcal activity.

In patients at risk of GNEB, particularly strains with ESBL, but without risk (or after exclusion of) of *P. aeruginosa*, ertapenem may be used.

Woodhead et al. Clin Microbiol Infect 2011;17 Suppl 6:E1-59 - PMID: 21951385






Not All Fluoroquinolones Are Equal

Here are the questions ...

When choosing an antibiotic, do we know


- 3. for Society
 - how to get "value for money" ?







How do you score the cost of a treatment ?










Scoring the cost of treatments



Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes. Res. 2011;3:29-36.





- Medical costs
 - ordering and acquiring the drug (generic)
 - storage in the hospital pharmacy
 - preparing the infusion (nurse's time and material)
 - infusion to the patient (twice daily) (nurse's time and material)
 - collecting and handling blood samples for monitoring (nurse's time)
 - laboratory serum level assay (cost and time)
 - maintaining the patient in the hospital for at least 10 days (daily cost)
 - managing nephrotoxicity (~ 5-10% of all patients)
- Non-medical costs
 - patient's absence from home for at least 10 days (need of external help)
 - patient's absence from work for at least 10 days (productivity loss)

The drug acquisition price of the generic vancomycin is only a small part of the total treatment cost !!!






- Medical costs
 - ordering and acquiring the drug (branded drug)
 - storage in the hospital pharmacy
 - proparing the infusion (nurse's time and material)
 - - infusion to the patient (twice daily) (nurse's time and material)-
 - collecting and handling blood samples for monitoring (nurse's time)
 - laboratory serum level assay (cost and time)
 - maintaining the patient in the hospital for at least 10 days (daily cost)
 - managing nephrotoxicity (~ 5-10% of all patients)
- Non-medical costs
 - patient's absence from home for at least 10 days(need of external help)
 - patient's absence from work for at least 10 days (productivity loss) \searrow

The <u>treatment</u> cost can be substantially reduced with an oral drug... offsetting the increased drug acquisition cost (branded)





What you wish to avoid ...






Bayer China Summit 2018 - Shanghai

A short personal view...



and what you may be looking for ...





Bayer China Summit 2018 - Shanghai

A short personal view...



Last words: strive for quality *

Many antibiotics are available as generics !



* based on previous presentations: see http://www.facm.ucl.ac.be/facm-conferences.htm

API: Active Pharmaceutical Ingredient PK: Pharmacokinetic PD: Pharmacodynamic





Its all a problem of balance and compass

业 BALANCE







Université catholique de Louvain

12 May 2018